BiotechTube

HTX-011 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Jun 1, 2015 → Sep 1, 2015

NCT ID
NCT02471898

About HTX-011 + Placebo

HTX-011 + Placebo is a phase 2 stage product being developed by Heron Therapeutics for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02471898. Target conditions include Analgesia.

What happened to similar drugs?

5 of 10 similar drugs in Analgesia were approved

Approved (5) Terminated (0) Active (5)
✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
✅HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
✅Bupivacaine HClHeron TherapeuticsApproved
✅Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
✅Bupivacaine Hydrochloride + Bupivacaine Hydrochloride + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
🔄Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02471898Phase 2Completed

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
42
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
31
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
50
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
42
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
27
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
29
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
40
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
40
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
30
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
33
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
25
Bupivacaine HClHeron TherapeuticsApproved
33
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
30
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
33
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
17